Study S002359

Does the Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT05895643
Acronym: SEMALCO
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 108
Start: 2023-06-13
Primary completion: 2025-07-31
Lead sponsor: Psychiatric Centre Rigshospitalet
Conditions: Alcohol Abuse; Alcohol Addiction; Alcohol Dependence; Alcohol Use Disorder
Interventions: DRUG:Semaglutide Injectable Product; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: REGISTRY:U1111-1286-6919

Registered primary outcomes

Change in heavy drinking days [From baseline to 26 weeks of treatment]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0007404	Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. Klausen MK, Lancet (London, England)	2026	Randomized trial	PMID 42070571 DOI	cites ClinicalTrials.gov:NCT05895643; registry reference DERIVED:42070571
R0008319	Blood phosphatidylethanol measurements indicate GLP-1 receptor stimulation causes delayed decreases in alcohol consumption. Jensen ME, Alcohol, clinical & experimental research	2025	Randomized trial	PMID 40123107 DOI	cites ClinicalTrials.gov:NCT05895643; registry reference DERIVED:40123107
R0010985	Does semaglutide reduce alcohol intake in Danish patients with alcohol use disorder and comorbid obesity? Trial protocol of a randomised, double-blinded, placebo-controlled clinical trial (the SEMALCO trial). Klausen MK, BMJ open	2025	Protocol	PMID 39779270 DOI	cites ClinicalTrials.gov:NCT05895643; registry reference DERIVED:39779270